High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms

被引:20
|
作者
Chan, David L. [1 ,2 ,3 ,4 ]
Bernard, Elizabeth J. [1 ]
Schembri, Geoffrey [1 ]
Roach, Paul J. [1 ]
Johnson, Meaghan [1 ]
Pavlakis, Nick [2 ,3 ]
Clarke, Stephen [2 ,3 ]
Bailey, Dale L. [1 ,4 ]
机构
[1] Royal North Shore Hosp, Dept Nucl Med, St Leonards, NSW, Australia
[2] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia
[3] Univ Sydney, Kolling Inst, Bill Walsh Translat Canc Res Lab, Sydney, NSW, Australia
[4] Sydney Vital Translat Canc Res Ctr, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Neuroendocrine neoplasm; Prognosis; Positron emission tomography; F-18-FDG PET/CT; CANCER; PARAMETERS; INDEX;
D O I
10.1159/000504673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction:18-Fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) avidity in neuroendocrine neoplasms (NENs) has been associated with higher-grade disease. F-18-FDG avidity and high SUVmax have been demonstrated to predict poor outcome. Quantitative metrics of F-18-FDG PET, specifically metabolic tumour volume (MTV) and total lesion glycolysis (TLG), have been shown to be prognostic factors in other malignancies, but these have not been investigated to date in NENs.Methods:Patients with NEN undergoing F-18-FDG at Royal North Shore Hospital from 2012 to 2018 were included. Images were analysed with automated segmentation (SUV cut-off of 4) followed by contour verification by a nuclear medicine physician and manual segmentation where required. Variables collected included patient age, histological grade, MTV, TLG, and SUVmax/SUVmean. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). Univariate (UV) and multivariate (MV) analyses were performed for OS and PFS for MTV and TLG separately. For UV analysis, the median MTV and TLG were used to dichotomise the cohort. MTV/TLG for NENs of different histological grade were compared using ANOVA.Results:One hundred and ninety patients were included (median age 63.5, 49% female). Primary site: 42% small bowel, 32% pancreas, 15% other gastrointestinal, 6% lung, 6% other. Grade for gastroenteropancreatic NENs and bronchial NEN: G1/typical carcinoid 37%, G2/atypical carcinoid 40%, G3/large-cell/small-cell neuroendocrine carcinoma 16%, unknown 8%. Median MTV was 4.83 mL (range 0-3,161 mL) and median TLG was 29.22. Patients with high MTV had worse median OS compared to those with low MTV (29.7 months vs. not reached, HR 4.1, 95% CI 2.25-7.49,p< 0.00001). Considered as a continuous variable, MTV predicted for poorer OS on UV (p< 0.00001) and MV (p= 0.003) analyses. Whilst histological grade was significant on both UV and MV, SUVmax was significant on UV (p< 0.00001) but not MV (p= 0.76). Tumours of higher grade had higher MTV (mean MTV - G1: 39.6 mL, G2: 107 mL, G3: 337 mL;p= 0.0001 by ANOVA).Conclusions:Quantitative analysis of F-18-FDG PET in NEN is feasible. High MTV/TLG are predictors of poor prognosis in NEN. Further analyses are underway to investigate a larger cohort of NEN patients.
引用
收藏
页码:950 / 958
页数:9
相关论文
共 50 条
  • [31] Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma
    Terada, Takayuki
    Tabata, Chiharu
    Tabata, Rie
    Okuwa, Hisaya
    Kanemura, Shingo
    Shibata, Esuke
    Nakano, Takashi
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (02) : 197 - 200
  • [32] Detection of aortic graft infection by 18-fluorodeoxyglucose positron emission tomography combined with computed tomography
    Tegler, Gustaf
    Sorensen, Jens
    Bjorck, Martin
    Savitcheva, Irina
    Wanhainen, Anders
    JOURNAL OF VASCULAR SURGERY, 2007, 45 (04) : 828 - 830
  • [34] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer
    E de Winton
    A G Heriot
    M Ng
    R J Hicks
    A Hogg
    A Milner
    T Leong
    M Fay
    J MacKay
    E Drummond
    S Y Ngan
    British Journal of Cancer, 2009, 100 : 693 - 700
  • [35] Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer
    Liong, Sue Y.
    Kochhar, Rohit
    Renehan, Andrew G.
    Manoharan, Prakash
    ANZ JOURNAL OF SURGERY, 2012, 82 (10) : 729 - 736
  • [36] THE USE OF 18-FLUORODEOXYGLUCOSE POSITRON EMISSION AND COMPUTED TOMOGRAPHY IN THE EVALUATION OF MARFAN SYNDROME PATIENTS
    Brili, Styliani V.
    Gkotzamanis, Viktor
    Kafouris, Pavlos
    Mystakidi, Vasiliki-Chara
    Sakalidis, Athanasios
    Antonopoulos, Alexis S.
    Oikonomou, Evangelos
    Anagnostopoulos, Constantinos
    Tsioufis, Konstantinos
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2017 - 2017
  • [37] Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas
    Sperti, C
    Pasquali, C
    Chierichetti, F
    Liessi, G
    Ferlin, G
    Pedrazzoli, S
    ANNALS OF SURGERY, 2001, 234 (05) : 675 - 680
  • [38] Effect of Corticosteroid Dose and Duration on 18-Fluorodeoxyglucose Positron Emission Tomography in Cardiac Sarcoidosis
    Okada, David R.
    Saad, Elie
    Wand, Alison L.
    Griffin, Jan M.
    Kasper, Edward K.
    Chen, Edward H.
    Chrispin, Jonathan
    Tandri, Harikrishna
    Solnes, Lilja B.
    Gilotra, Nisha A.
    JACC-CARDIOVASCULAR IMAGING, 2020, 13 (05) : 1280 - 1282
  • [39] Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
    Bangerter, Markus
    Kotzerke, Joerg
    Griesshammer, Martin
    Elsner, Klaus
    Reske, Sven Norbert
    Bergmann, Lothar
    Acta Oncologica, 38 (06): : 799 - 804
  • [40] Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
    Bangerter, M
    Kotzerke, J
    Griesshammer, M
    Elsner, K
    Reske, SN
    Bergmann, L
    ACTA ONCOLOGICA, 1999, 38 (06) : 799 - 804